TRACON Pharmaceuticals, Inc.Find Ratings Reports
TRACON PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. TRACON PHARMACEUTICALS INC has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 296.76% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||0.35||0.0|
|Net Income ($mil)||-8.94||-4.45|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||25.58||14.45|
|Total Assets ($mil)||26.8||15.65|
|Total Debt ($mil)||2.76||4.51|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||-2556.07||0.0|
|Return on Assets||-83.22||-112.5|
|Return on Equity||-187.21||-586.31|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||15.5||7.77|
|Div / share||0.0||0.0|
|Book value / share||0.77||0.39|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||278283.0||148592.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.94 indicates a premium versus the S&P 500 average of 4.43 and a significant discount versus the subsector average of 10.43. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, TRACON PHARMACEUTICALS INC proves to trade at a discount to investment alternatives.
|TCON NM||Peers 31.52||TCON NM||Peers 19.38|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
TCON's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
TCON's P/CF is negative making the measure meaningless.
|TCON NM||Peers 17.23||TCON NA||Peers 0.35|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
TCON's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|TCON 4.94||Peers 10.43||TCON 63.89||Peers 236.90|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
TCON is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, TCON is expected to significantly trail its peers on the basis of its earnings growth rate.
|TCON 168.31||Peers 1442.02||TCON NA||Peers 1994.96|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
TCON is trading at a significant discount to its subsector on this measurement.
Neutral. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share.
The growth rate for TCON is not available.